REFERENCES
1. Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. ; FINE-ONE Investigators. Finerenone in type 1 diabetes and chronic kidney disease. N Engl J Med. 2026;394:947-57.
2. Palmer BF. Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes. Diabetes Obes Metab. 2023;25:1434-43.
3. Heerspink HJL, Collier WH, Chaudhari J, et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med. 2026;32:281-7.
4. Tuttle KR, Ji L, Mathieu C, Rosen J. Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: a review. Diabetes Obes Metab. 2026;28:16-26.
5. Hollenberg NK, Stevanovic R, Agarwal A, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int. 2004;65:1435-9.
6. Sanyal D, Mukhopadhyay P, Ghosh S. Prevalence and impact of diabetes and prediabetes on presentation and complications of primary hyperaldosteronism at diagnosis. World J Clin Cases. 2024;12:3332-9.
7. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension. 2012;59:375-81.
8. Pang Y, Gong S, Tetti M, et al. EGR1 regulates oxidative stress and aldosterone production in adrenal cells and aldosterone-producing adenomas. Redox Biol. 2025;80:103498.
9. Ohira M, Kawagoe N, Kameyama C, Kondou Y, Igarashi M, Ueshiba H. Association of serum cortisol with insulin secretion and plasma aldosterone with insulin resistance in untreated type 2 diabetes: a cross-sectional study. Diabetol Metab Syndr. 2025;17:144.
10. Prasad D, Drysch A, Upadhyay D, Neilson EG. The story of aldosterone escape. J Am Soc Nephrol. 2026;37:164-71.
11. Jia G, Lastra G, Bostick BP, et al. The mineralocorticoid receptor in diabetic kidney disease. Am J Physiol Renal Physiol. 2024;327:F519-31.
12. Lee YB, Hwang HJ, Kim E, Lim SH, Chung CH, Choi EH. Hyperglycemia-activated 11β-hydroxysteroid dehydrogenase type 1 increases endoplasmic reticulum stress and skin barrier dysfunction. Sci Rep. 2023;13:9206.
13. Shimanoe C, Matsumoto A, Nishida Y, et al. Urinary cortisol-to-cortisone ratio levels modify the association between diabetes and hypertension: a cross-sectional study of 6931 older adults. Hypertens Res. 2025;48:2349-57.
14. Liu YJ, Nakagawa Y, Ohzeki T. Gene expression of 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidneys of insulin-dependent diabetic rats. Hypertension. 1998;31:885-9.
15. Janssen JAMJL. New insights into the role of insulin and hypothalamic-pituitary-adrenal (HPA) axis in the metabolic syndrome. Int J Mol Sci. 2022;23:8178.
16. Lacy ME, Gilsanz P, Karter AJ, Quesenberry CP, Pletcher MJ, Whitmer RA. Long-term glycemic control and dementia risk in type 1 diabetes. Diabetes Care. 2018;41:2339-45.
17. Schmiedek P, Sadée W, Baethmann A. Cerebral uptake of a 3 H-labelled spirolactone compound in the dog. Eur J Pharmacol. 1973;21:238-41.
18. Cai X, Li N. Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study. Pharmaceuticals. 2023;16:57.
